Prometheus Biosciences is a biotechnology company developing a precision medicine approach to the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting with inflammatory bowel disease. Co. utilizes its proprietary precision medicine platform, Prometheus360™, which includes a gastrointestinal bioinformatics database and sample biobank, to identify therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, Co. is developing companion diagnostic tests designed to identify patients more likely to respond to our therapeutic candidates. We show 9 historical shares outstanding datapoints in our coverage of RXDX's shares outstanding history.
Understanding the changing numbers of RXDX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RXDX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RXDX by allowing them to research RXDX shares outstanding history
as well as any other stock in our coverage universe. |
Free RXDX Email Alerts:
Video: Shares Outstanding Importance
